Key result
Bivalirudin provides similar or reduced major bleeding rates compared with heparin and exhibits a low immunogenic profile.
Why the study?
Does bivalirudin provide effective anticoagulation with similar or reduced bleeding compared to heparin in patients undergoing cardiovascular procedures or with heparin-induced thrombocytopenia?
Does bivalirudin provide effective anticoagulation with similar or reduced bleeding compared to heparin in patients undergoing cardiovascular procedures or with heparin-induced thrombocytopenia?
Bivalirudin is a reliable and efficient direct thrombin inhibitor for anticoagulation during cardiovascular procedures, offering similar or reduced bleeding rates compared to heparin.
No takes yet. Share an insight, caveat, or question.
Bivalirudin use in PCI and procedures requires updated RCTs; leaves open optimal anticoagulation choices in contemporary practice.
Car et al. (2010) conducted a review in Percutaneous coronary interventions, cardiac and endovascular surgery, heparin-induced thrombocytopenia. Bivalirudin vs. Heparin was evaluated. Bivalirudin provides similar or reduced major bleeding rates compared with heparin and exhibits a low immunogenic profile.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: